Okour et al., Journal of Pharmacokinetics and Pharmacodynamics, May 13, 2020, doi:10.1007/s10928-020-09689-x (Peer Reviewed) Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome
Odds of PCR-positive decrease by 53% for each unit increase in HCQ log-concentration. Similarly, the odds decrease by 61%, and by 12% for each day increase, and for azithromycin co-treatment, respectively. Computes the minimum HCQ concentration needed based on severity, and corresponding dosage regimens. A loading dose is found to be important. For LRTI and URTI patients the addition of AZ is needed. Extended analysis of Gautret et al. using the observed HCQ concentrations and pharmacokinetic analysis to compute concentrations for all days.
Okour et al., 5/13/2020, peer-reviewed, 3 authors.